LONDON - Amgen Inc. received a double blow against the patent covering its blockbuster drug erythropoietin (EPO) when the UK House of Lords reversed an earlier legal decision and ruled the claims of the patent are too broad, while at the same time upholding an earlier judgment that Transkaryotic Therapies Inc.'s method of producing EPO does not infringe Amgen's EPO patent. (BioWorld International)

Human Genome Sciences Inc.'s Albugon for diabetes drew a development and commercialization deal worth up to $183 million with GlaxoSmithKline plc, which gets worldwide rights to albumin-glucagon-like peptide-1. (BioWorld Today)